Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Mar;17(3):133.
doi: 10.1038/s41571-019-0325-y.

HER2-targeted agents overcome resistance

Peter Sidaway  1
Affiliations
Comment

HER2-targeted agents overcome resistance

Peter Sidaway. Nat Rev Clin Oncol. 2020 Mar.
No abstract available

PubMed Disclaimer

Comment on

  • Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
    Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators. Modi S, et al. N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11. N Engl J Med. 2020. PMID: 31825192 Free PMC article. Clinical Trial.
  • Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
    Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Müller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP. Murthy RK, et al. N Engl J Med. 2020 Feb 13;382(7):597-609. doi: 10.1056/NEJMoa1914609. Epub 2019 Dec 11. N Engl J Med. 2020. PMID: 31825569 Clinical Trial.

References

Original articles
    1. Murthy, R. K. et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1914609 (2019) - DOI - PubMed
    1. Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1914510 (2019) - DOI - PubMed - PMC